- Welcome and Introductions
- Primary Management of Chronic-Phase CML
- Selecting first-line therapy
- Monitoring response to TKI therapy
- Managing Toxicities, Promoting Adherence, and Engaging the Patient
- Changing Therapy
- When to consider changing therapy
- Options after first-line TKI therapy
- Future Directions
- Closing Remarks, Question and Answer Session, and Discussion of Available Online Resources and Tools
Date / Time
Jorge Cortes, MD
Director, Georgia Cancer Center
Eminent Scholar, Georgia Research Academy
The goal of this activity is to improve the competence of all members of the interdisciplinary team in applying the latest guidance and clinical data in the management of individuals with chronic myeloid leukemia.
This program is intended for hematologists/oncologists, pediatric hematologists, pharmacists, nurse practitioners, hematology/oncology nurses, and other healthcare professionals who care for patients with CML.
Upon completion of this activity, participants should be able to:
- Compare the mechanisms of actions of available TKIs to block BCR-ABL activity and the associated toxicity profiles of these agents when used to treat patients with CML
- Increase patient involvement in the initiation of treatment, monitoring of response, managing toxicity, and optimizing adherence
- Select individualized therapy for patients with chronic-phase CML, considering patient goals, age, medical history, comorbidities, risk score, previous CML treatment, and BCR-ABL1 mutation status
- Monitor treatment responses and determine optimal timing for therapy changes
- Evaluate the available evidence, potential predictive factors, patient preferences, and expert recommendations guiding potential therapy discontinuation and treatment-free remissions
- Optimally sequence second-line, third-line, and later therapeutic strategies to overcome resistance after previous TKI failure
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-222-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.